PCSK9 Inhibitor Trends in Type 1 Diabetes
PCSK9 had a significant correlation with hemoglobin A1c, triglycerides, total cholesterol, LDL cholesterol, and apolipoprotein B in patients with type 1 diabetes.
Cholesterol
Total Cholesterol, Low-Density Lipoprotein Cholesterol Levels Affect Parkinson’s Risk
A decreased risk in Parkinson’s disease has been associated with total serum cholesterol and low-density lipoprotein cholesterol in men not on statin therapy.
Statins May Increase Risk for Mortality in Type 2 Diabetes
In a study,patients with type 2 diabetes presented better glycemic control and had higher risk for mortality when not taking statins.
Cholesterol Significantly Reduced by Blocking Angiopoietin-like 3 Gene
Two research groups successfully reduced cholesterol in humans to block the angiopoietin-like 3 gene.
Long-Term Outcomes of Evacetrapib on Cardiovascular Outcomes
Evacetrapib does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes in patients with high-risk vascular disease.
Is Pravastatin Effective as Primary Prevention Against CHD Events in Elderly?
No differences were observed between pravastatin and usual care for CHD events, cause-specific deaths, stroke, cancer, and combination fatal CHD or nonfatal MI.
Targeted Approach Needed for Cholesterol Screenings
Study shows prevalence of atherosclerotic cardiovascular disease risk among adults under 50 without diabetes is low.
Hypertension, High Cholesterol Risks Similar for ‘Social Smokers’
Social smokers have the same risk level for hypertension and elevated cholesterol as regular smokers.
Reported Muscle-Related Adverse Events Increase When Aware of Statin Use
Muscle-related adverse event reports increase when patients and doctors know that statins are being used.
Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin
Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.
- Loading...
Loading...
Loading... 
Loading...